血液科

订阅

MedSci主页 / 所有栏目 / 血液科

IJLH：体外研究依诺肝素对直接口服Xa因子抑制剂血药浓度的影响

2019-07-22 不详 MedSci原创

抑制剂血药浓度
关注

在测量直接口服抗凝血剂(DOAC)水平时，依诺肝素和直接口服Xa因子抑制剂(xabans: apixaban, edoxaban, rivaroxaban)同时给药可能会导致抗Xa活性重叠的问题。本研究的目的是在体外评估增加依诺肝素浓度对xaban血浆水平干扰的程度。 研究人员对7份血浆样品分别加入固定浓度的阿哌沙班、依诺肝素、利伐沙班和依诺肝素(0,0.125、0.250、0.50、1.0

在测量直接口服抗凝血剂(DOAC)水平时，依诺肝素和直接口服Xa因子抑制剂(xabans: apixaban, edoxaban, rivaroxaban)同时给药可能会导致抗Xa活性重叠的问题。本研究的目的是在体外评估增加依诺肝素浓度对xaban血浆水平干扰的程度。

研究人员对7份血浆样品分别加入固定浓度的阿哌沙班、依诺肝素、利伐沙班和依诺肝素(0,0.125、0.250、0.50、1.0、1.50和2.0 IU/mL)。评价的显色试验包括Biophen DiXaI和Biophen肝素LRT (Hyphen BioMed)、Berichrom肝素和Innovance肝素(Siemens)、STA‐液体抗‐Xa (Stago Diagnostics)、Technochrom抗‐Xa (Technoclone)和hemsil液体抗Xa (Werfen)。

依诺肝素的存在导致DOAC水平增加，过度估计与抗Xa测定和样品中的肝素浓度相关。 依诺肝素0.125 IU / mL的样本过度估计值最低，依诺肝素2.0 IU / mL的样本最高（阿哌沙班的0％，3.1％和7.4％vs 583.8％，526.1％和415.2％，edoxaban和rivaroxaban）。 与其他方法相比，Biophen DiXaI显示出干扰较低（在依诺肝素2.0 IU / mL存在下最大高估：Biophen DIXaI给药利伐沙班56.4％，而Berichrom肝素给药阿哌沙班583.8％）。

研究表明，依诺肝素的存在干扰了显色抗Xa法测定xabans，造成DOAC水平的错误升高，过高的估计与抗Xa法和样本中的肝素浓度相关。

原始出处：

Michela Cini, Cristina Legnani, An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852061, encodeId=095518520612c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Aug 23 14:47:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951141, encodeId=6ea0195114117, content=<a href='/topic/show?id=b54b89956db' target=_blank style='color:#2F92EE;'>#血药浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89956, encryptionId=b54b89956db, topicName=血药浓度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun May 17 14:47:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777363, encodeId=fc7b1e77363c9, content=<a href='/topic/show?id=5ad518e987f' target=_blank style='color:#2F92EE;'>#Xa因子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18798, encryptionId=5ad518e987f, topicName=Xa因子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d13c39165560, createdName=hxzhang, createdTime=Mon Oct 28 03:47:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378989, encodeId=7e6413e898946, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Jul 24 00:47:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544584, encodeId=5e851544584d1, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Jul 24 00:47:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-08-23 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1852061, encodeId=095518520612c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Aug 23 14:47:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951141, encodeId=6ea0195114117, content=<a href='/topic/show?id=b54b89956db' target=_blank style='color:#2F92EE;'>#血药浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89956, encryptionId=b54b89956db, topicName=血药浓度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun May 17 14:47:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777363, encodeId=fc7b1e77363c9, content=<a href='/topic/show?id=5ad518e987f' target=_blank style='color:#2F92EE;'>#Xa因子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18798, encryptionId=5ad518e987f, topicName=Xa因子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d13c39165560, createdName=hxzhang, createdTime=Mon Oct 28 03:47:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378989, encodeId=7e6413e898946, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Jul 24 00:47:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544584, encodeId=5e851544584d1, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Jul 24 00:47:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2020-05-17 xiongliangxl

    #血药浓度#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1852061, encodeId=095518520612c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Aug 23 14:47:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951141, encodeId=6ea0195114117, content=<a href='/topic/show?id=b54b89956db' target=_blank style='color:#2F92EE;'>#血药浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89956, encryptionId=b54b89956db, topicName=血药浓度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun May 17 14:47:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777363, encodeId=fc7b1e77363c9, content=<a href='/topic/show?id=5ad518e987f' target=_blank style='color:#2F92EE;'>#Xa因子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18798, encryptionId=5ad518e987f, topicName=Xa因子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d13c39165560, createdName=hxzhang, createdTime=Mon Oct 28 03:47:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378989, encodeId=7e6413e898946, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Jul 24 00:47:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544584, encodeId=5e851544584d1, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Jul 24 00:47:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-10-28 hxzhang

    #Xa因子抑制剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1852061, encodeId=095518520612c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Aug 23 14:47:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951141, encodeId=6ea0195114117, content=<a href='/topic/show?id=b54b89956db' target=_blank style='color:#2F92EE;'>#血药浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89956, encryptionId=b54b89956db, topicName=血药浓度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun May 17 14:47:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777363, encodeId=fc7b1e77363c9, content=<a href='/topic/show?id=5ad518e987f' target=_blank style='color:#2F92EE;'>#Xa因子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18798, encryptionId=5ad518e987f, topicName=Xa因子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d13c39165560, createdName=hxzhang, createdTime=Mon Oct 28 03:47:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378989, encodeId=7e6413e898946, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Jul 24 00:47:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544584, encodeId=5e851544584d1, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Jul 24 00:47:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-07-24 xiaogang317

    #依诺肝素#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1852061, encodeId=095518520612c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Aug 23 14:47:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951141, encodeId=6ea0195114117, content=<a href='/topic/show?id=b54b89956db' target=_blank style='color:#2F92EE;'>#血药浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89956, encryptionId=b54b89956db, topicName=血药浓度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun May 17 14:47:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777363, encodeId=fc7b1e77363c9, content=<a href='/topic/show?id=5ad518e987f' target=_blank style='color:#2F92EE;'>#Xa因子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18798, encryptionId=5ad518e987f, topicName=Xa因子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d13c39165560, createdName=hxzhang, createdTime=Mon Oct 28 03:47:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378989, encodeId=7e6413e898946, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Jul 24 00:47:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544584, encodeId=5e851544584d1, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Jul 24 00:47:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-07-24 12498974m55暂无昵称

    #浓度#

    0

相关资讯

J Cell Biochem：Notch1蛋白的抑制能够减少肿瘤生长

Notch1在许多癌症中，包括前列腺癌（PCa），起着促进癌症的作用。利用γ-分泌酶抑制剂对Notch家族成员的整体抑制能够在小鼠模型中显著的抑制PCa的生长。然而，Notch的整体抑制表现出了显著的毒性，原因是在正常的细胞生理中，许多不同的Notch家族成员均具有相关的功能。最近，有研究人员将雄激素依赖的VCaP和不依赖雄激素的DU145细胞系对小鼠进行皮下注射。这些小鼠进行对照抗体1B7.11

Cancer Discov：第四代EGFR抑制剂，突破点在哪？

EGFR，即表皮生长因子受体（epidermal growth factor receptor），也叫HER1或ErbB1，是人表皮生长因子受体（HER）家族成员之一。除了HER1（ErbB1，EGFR）之外，HER家族还包括HER2（ErbB2，neu）、HER3（ErbB3）及HER4（ErbB4）。

Int J Cardiol：免疫检查点抑制剂相关性心肌炎的诊断

由此可见，免疫检查点抑制剂相关性心肌炎的特征是心肌肌钙蛋白水平升高和非特异性心电图改变。早期冠状动脉造影可将其与心肌缺血或心肌梗塞区分开来。

Int J Impot Res：未确诊的前驱糖尿病状态与磷酸二酯酶5型抑制剂效果的减弱相关

磷酸二酯酶5型抑制剂（PED5i）在阴茎勃起功能障碍（ED）患者和未确诊的前驱糖尿病（PreDM）患者中的治疗效果还缺乏分析。最近，有研究人员在一个没有经历PED5i 治疗的ED患者群体中评估了口服PED5i治疗的响应速度和预测因子，这些患者血糖正常或者PreDM或者患有糖尿病（DM）。研究包括了466名男性。研究发现，血糖正常、PreDM或者DM的患者比例分别为253 (56.7%)、105 (

Diabetes Obes Metab：钠-葡萄糖协同转运蛋白-2抑制剂致急性肾损伤

虽然这些数据表明SGLT2抑制剂可以保护易受伤害的2型糖尿病患者免于AKI，并且有必要进行前瞻性研究来评估肾脏保护的这一效应。

Iran Biomed J：新型聚腺苷二磷酸核糖聚合酶（RARP）抑制剂AZD2461能够下调VEGF表达和诱导前列腺癌细胞凋亡

前列腺癌（PCa）是一种异质性疾病，目前的治疗手段并不是基于分子层面。最近有报道表明，RARP抑制剂对具有同源重组缺陷的细胞具有明显的毒性，尤其是那些BRCA变异背景的细胞。因此，最近有研究人员评估了是否PTEN表达状态对侵入性PCa细胞对RARP抑制剂AZD2461的敏感性具有影响。研究发现，MTT结果表明了AZD2461对PC-3细胞的抑制作用要比DU145细胞显著更高（处理后48小时的IC5